At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 60 enrolled
Drug / intervention
VAL-181388 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non-endemic Chikungunya Region
In Brief
A Phase 1 clinical trial evaluating VAL-181388 and Placebo for Chikungunya Virus. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus
CountriesUnited States
CollaboratorsDefense Advanced Research Projects Agency
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedOct 2017
Primary CompletionMar 2019
TodayJul 2026
First PostedOct 30, 2017
Enrollment StartJul 19, 2017
Primary CompletionMar 19, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.7 years ago
Interventions
VAL-181388biological
Escalating dose levels
Placeboother
Saline